1 1 Auditing: A Panel Discussion of Evolving Compliance Strategies Ann E Lewis, VP and Senior Counsel, US Healthcare Law Compliance (Bristol-Myers Squibb)

Slides:



Advertisements
Similar presentations
ETHICS AS CULTURE KEY ELEMENTS Stage One (primary) – Key Elements of a Culture of Ethics Appoint an ethics program manager to oversee your ethics-related.
Advertisements

Board Governance: A Key to Quality Organizations
4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.
Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
PwC Medical Device Compliance Survey Discussion of Survey Results.
1 AUDIT AND AUDIT RESOLUTION Peg Rosenberry, Director of Grants Management Claire Moreno, Audit Liaison, Office of Grants Management 9/18/2009 AMERICORPS.
Auditing, Assurance and Governance in Local Government
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
Contractor Code of Business Ethics and Conduct Laura K. Kennedy Senior Vice President, Ethics and Compliance SAIC.
COMPLIANCE AND INTEGRITY IN GOVERNMENT AND NON-PROFIT ORGANIZATIONS Michael E. Nawrocki, CPA Managing Partner Nawrocki Smith LLP, CPA’s Historical Perspective.
1 INTERNAL CONTROLS A PRACTICAL GUIDE TO HELP ENSURE FINANCIAL INTEGRITY.
External Quality Assessments
SAFA- IFAC Regional SMP Forum
Purpose of the Standards
Supplier Ethics: Program Checklist
Corporate Ethics Compliance *
Auditing Standards IFTA\IRP Audit Guidance Government Auditing Standards (GAO) Generally Accepted Auditing Standards (GAAS) International Standards on.
Control environment and control activities. Day II Session III and IV.
Internal Auditing and Outsourcing
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
© 2009 The McGraw-Hill Companies, Inc. All rights reserved. 1 McGraw-Hill Chapter 5 HIPAA Enforcement HIPAA for Allied Health Careers.
Organization Mission Organizations That Use Evaluative Thinking Will Develop mission statements specific enough to provide a basis for goals and.
Programmatic and Fiscal Compliance as a Team Effort 2014 Project Director Training & Annual Meeting1.
D-1 McGraw-Hill/Irwin ©2005 by the McGraw-Hill Companies, Inc. All rights reserved. Module D Internal, Governmental, and Fraud Audits “I predict that audit.
Christie Stelling, CPA, CIA Assoc. Director, Finance Financial Controls.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
CORPORATE COMPLIANCE Tim Timmons Vice President Compliance and Regulatory Services Health Future, LLC.
Effective Management and Compliance 1 ANA GRANTEE MEETING  FEBRUARY 5, 2015.
Developing and Implementing an Effective Compliance Program Mary Sacilotto,BA,CHC Chief Compliance Officer Alliance, Inc.
How to Develop Internal Monitoring Programs SEVENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM Stephen F. Mohr Global.
© 2013 Cengage Learning. All Rights Reserved. 1 Part Four: Implementing Business Ethics in a Global Economy Chapter 9: Managing and Controlling Ethics.
©2006 Prentice Hall Business Publishing, Auditing 11/e, Arens/Beasley/Elder Internal and Governmental Financial Auditing and Operational Auditing.
©2010 Prentice Hall Business Publishing, Auditing 13/e, Arens/Elder/Beasley Internal and Governmental Financial Auditing and Operational Auditing.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
Why the Office of Compliance and Ethics was Created
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
1 Today’s Presentation Sarbanes Oxley and Financial Reporting An NSTAR Perspective.
1 Kingsley Karunaratne, Department of Accounting, University of Sri Jayewardenepura, Colombo - Sri Lanka Practice Management.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Pre-Conference III: Auditing, Monitoring and Effective Internal Investigations Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
McGraw-Hill/Irwin © The McGraw-Hill Companies 2010 Audit Planning and Types of Audit Tests Chapter Five.
Practice Management Quality Control
PwC Medical Device Compliance Survey Discussion of Survey Results March 30, 2006.
Chapter 21 Internal, Operational, and Compliance Auditing McGraw-Hill/IrwinCopyright © 2014 by The McGraw-Hill Companies, Inc. All rights reserved.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
D1.HRD.CL9.06 D1.HHR.CL8.07 D2.TRD.CL8.09 Slide 1.
Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.
Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved.McGraw-Hill/Irwin.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
A Guide for Management. Overview Benefits of entity-level controls Nature of entity-level controls Types of entity-level controls, control objectives,
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.
1 Compliance vs. the Law Department: How to Work Together Michael Dusseau Senior Director, Compliance North America Schering-Plough David Ralston, Esq.
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
Copyright © 2015 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
The IVD Australia Code of Conduct Edition 2.1
MGMT 452 Corporate Social Responsibility
Internal and Governmental Financial Auditing and Operational Auditing
TERMS OF REFERENCE - FINANCE COMMITTEE
Refuah Community Health Collaborative (RCHC) PPS
The Most Important Element to Assure That Your Sales and Marketing Compliance Program is Working Effectively: Monitoring and Auditing Kelly B. Freeman,
Risk Management: why and how to protect your health center
Lilly Grant Funding Disclosure May 27, 2008
The Elements of appropriate Internal Controls
Developing an Effective Compliance Training Program for Pharmaceutical Sales Personnel Kelly B. Freeman, Ph.D. Director, US Affiliate, Compliance and.
Industry Induction Course
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Internal Audit’s Role in Preventing Fraud and Corruption
An overview of Internal Controls Structure & Mechanism
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
Presentation transcript:

1 1 Auditing: A Panel Discussion of Evolving Compliance Strategies Ann E Lewis, VP and Senior Counsel, US Healthcare Law Compliance (Bristol-Myers Squibb) Monica Jonhart, Director, Auditing, US Healthcare Law Compliance (Bristol-Myers Squibb) Michael Dusseau, Senior Director, Global Compliance (Schering-Plough) Kelly B. Freeman, Director, US Affiliate, Compliance and Ethics (Lilly)

2 2 Disclaimer The opinions expressed herein are the panelists’ own, are based on their experience and knowledge in the industry, and do not necessarily represent the opinions of their current or any former employer.

3 3 Compliance Auditing: A Relatively New Development Scope of our discussion: Compliance Auditing in sales, marketing and medical affairs Historically, areas addressed by legal direction, high level policy, and legal training Violations of policy were addressed on a one-off basis through investigations Contrast to well established financial, gmp and glp auditing practices designed to prevent violations

4 4 OIG Guidance Use of audits and risk evaluation techniques to –Monitor compliance –Identify problem areas –Assist in the reduction of identified problems Nature of reviews –Prospective systemic review of processes, protocols, and practices –Retrospective review of actual practices Also evaluate whether –Policies cover identified risk areas –Policies were implemented and communicated –Polices were followed

5 5 Sentencing Guidelines The organization shall take reasonable steps To ensure that the organization’s compliance and ethics program is followed, including monitoring and auditing to detect criminal conduct To evaluate periodically the effectiveness of the organization’s compliance and ethics program

6 6 A survey of Five CIAs : the government’s areas of concern for external review and internal audit Serono Schering-Plough Astra Zeneca TAP Pfizer

7 7 IRO Responsibilities Promotional and Product Services Engagement Educational Sponsorship Arrangements Review Government Pricing and Medicaid Drug Rebate Related Functions Managed Care Expenditures Engagement

8 8 IRO Systems Reviews (follow the policies) Field Activities: MSL’s and Off-label requests MSL interactions with field reps MSL compensation Call plan development Samples Procedures Speaker Programs/ Marketing Business need for HCP engagements as speakers; no tracking of speaker prescribing habits FMV and speaker tier criteria Verification of work product before payment Reimbursement services Document controls and promotional program approval processes

9 9 IRO Systems Reviews Cont’d Grant Process and Research Activities Grant funding criteria, including procedures for request Disclosure of support Independence of programs funded by company

10 IRO Transactions Review (“follow the documents”) Retention of HCPs, purchasers and/or prescribers of company’s products for speaking or consulting arrangements and review of related agreements Awarding or payment of research grants or other participation in research activities and review of related agreements Awarding or payment of charitable contributions or sponsorships and review of related agreements Provision of gifts, meals, entertainment or other items of value to HCPs and review of related field and marketing expense reports

11 Company (internal) audit requirements under CIAs Serono Serostim Inquiry Report- quarterly report provided to compliance officer regarding all off-label inquiries for Serostim Review of Detailing Sessions – verbatim/records obtained from outside, independent entity reflecting the content of detailing interactions between sales reps and HCPs for two covered products (annually selected by the OIG) Internal audit option (upon request and approval from OIG) available for Education Sponsorship and Promotional and Product Services Review for the fourth and fifth annual reporting periods

12 Company (internal) audit requirements under CIAs (cont’d) Schering Specialty Field Sales Force Promotion Monitoring Program – program to identify off-label promotion by specialty field sales teams through Global Compliance & Business Practice Group observation of field activities Monitoring and Review of Off-Label Information – off-label inquiry analysis of requests for medical information. Message Recall Monitoring Program – analysis of commercially available studies generated by an independent outside company regarding physician recall of marketing messages delivered by specialty field sales teams

13 Company (internal) audit requirements under CIAs (cont’d) AstraZeneca Medicaid Rebate Review – internal audit group to assist company in ensuring accuracy of Best Price reporting (subject to IRO verification and review) Sales and Marketing Review - internal audit group to conduct annual review for three (3) business centers including interviews of employees and sales and marketing documents relating to Promotional and Product Services (subject to IRO verification and review) TAP Internal audit option (upon request and approval from OIG) available for Drug Price Reporting Engagement and Sales and Marketing Engagement after the fourth annual reporting period

14 Factors Driving Compliance Auditing – Why We Audit OIG Guidance and other government direction Compliance with the proliferation of state laws, and federal laws (anti kickback, FDCA, PDMA, other federal healthcare program laws) Compliance with the PhRMA Code, ACCME and other voluntary guidelines Internal Policies Perception auditing – the NY Times test (like modest meals) Consent Decrees, DPAs, CIAs Culture change: assuring people understand the organization’s values

15 Benefits of Monitoring and Auditing Assure compliance with policies –Document that policies are being followed –If they aren’t, you want to find it and fix it yourself Ascertain effectiveness of other program elements –Policy language –Training –Communication programs Foster relationships with business partners –Putting a face with the compliance program –Opportunities to coach and share the learning –Opportunities to understand business challenges –It’s not an “ivory tower” compliance program

16 Risk areas by Function not by Department 4 P’s + Product …quality, safety, functionality Price … retail price, discounts, rebates Place … distribution channel, market coverage Promotion … advertising, sales promotion, personal selling, publicity People … trained, motivated, skill set Process … practices and behaviors

17 Comparing Financial Auditing & Compliance Auditing Financial AuditingCompliance Auditing Purpose Provide assurance that data presented in financial statements presented in accordance with GAAP Provide assurance that activities are conducted in accordance with compliance standards Objectives Transactions are complete, accurate, valid and have occurred; access is restricted Intent, content, and context of activities are as important as following standard procedures Characteristics Past records only Financial focus Past and Live Components Activity focus Outcomes Adjustments, Corrections, Restatements Process Improvements, Training, Disciplinary Actions

18 Continuous Improvement Train Develop Audit Programs Risk Based Audits Report Findings Issue Guidance Revise Processes Develop Policy Develop Audit Toolkit Conduct Audit Present specific findings to management Share findings with process improvement workstream Issue Audit Report Develop and issue guidance based on audit findings

19 Auditing - Monitoring AuditingMonitoring Purpose Provide assurance that processes and activities comply with laws, regulations and policies Measure activities to assure achievement of operational & compliance objectives Scope/Focus Internal controls and processes related to stated business standards and policies Activities and transactions related to a specific function or department Characteristics Systematic and structured review conducted by independent staff Ongoing process of checking and measuring performance conducted by operations & compliance Frequency Schedule determined by risk based audit plan Schedule determined by frequency of transaction Outcomes Formal audit report with findings and recommendations Variance analyses, exception reports, metrics

20 How do you determine areas that require audit? Changes in Policy or Process Areas of high legal risk (payments to HCPs, grants) Areas of organizational change Areas where stretch financial targets have been set Risks uncovered through monitoring; Compliance review of audit plan

21 Auditing Structures: Where Do Companies’ Compliance Audit Functions Sit? One model has Compliance Audit within an OIG (seven elements) comprehensive compliance program; facilitates integration with policy and process development Another model: auditing is independent; reports up through Internal Audit Where does internal audit sit within Corporate structure?

22 How do you interact with the Businesses? When do you need to advise the business of an audit- and when do you not? –Consider whether discussion will prospectively affect behavior (e.g. notification of an audit of off- label requests to Medical Affairs) –Understanding of the purpose of audits encourages cooperation (change in culture; recognition that audit identifies problems before the regulators come in) How do you stay in touch with evolving business strategies? –Where are your touch points-e.g Compliance integration in business councils, decision making fora

23 Does the Imposition of a CIA or Consent Decree Change Your Audit Approach? Government may be focused on different risks (consistency across CIAs) Mandatory reporting of “reportable events” may affect the continuous improvement focus IRO evaluation of systems and transactions may enhance or redirect auditing efforts

24 Role of the Legal Department in Auditing When do you want your lawyers involved? Expertise in subject matter (for example, current off-label issues that should be spotted in a speaker program or field force audit) When is it appropriate to conduct an audit under privilege? Can there be a privileged audit when operating under a CIA or Consent Decree? What other expertise is appropriate to enlist?

25 Specific Risk Area Issues in Compliance Auditing & Monitoring: Field Force Communications and interactions at training identify areas of risk or concern Hotline calls and investigations Documents: expense reports, sample accountability, performance management documents (e.g. Manager documentation of field observation), call notes, action plans, district expenses, compliance training records Monitoring through rep rides: direct field force observation  who does the observation (separation of those who monitor from those who provide advice and assistance)  length of observation: spending more than one day with a single representative may be a “best practice” (viewing rep conduct and customer expectations)

26 Specific Risk Area Issues In Compliance Auditing and Monitoring: Speaker Programs Retrospective: Past ProgramsProspective: Live Programs Attributes –Ensure compliance with company’ policy Documentation –Program Content Agenda Slide deck Approval Attendance –Speakers Selection criteria Contracts Training Compensation –Reconciliation Budget versus actual Observation –Content Presentation v. Social Approved slide deck Fair balance and safety data Unsolicited questions –Audience Physicians or other HCP Others - no spouse or guests –Venue Following policy Modest Challenges –Sample size –Multiple stakeholders –Schedules –Interactions with attendees

27 Metrics and Data Sources How is compliance measured? What constitutes a comprehensive audit? How do you track trends and issues? Adequacy of data bases: what spend is captured in your data bases, and how does that affect your auditing practices?

28 When do you turn compliance over to the business? Field monitoring of programs: Representatives have responsibility for monitoring speaker adherence to policy Modest meals and sample reconciliation: Performance issue; sales management, business operations report and monitor But, we have a long way to go before the audit/monitoring function is obsolete!